Zacks Research Predicts Amgen’s Q4 Earnings (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at Zacks Research reduced their Q4 2024 earnings per share estimates for Amgen in a report issued on Wednesday, November 20th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $4.86 per share for the quarter, down from their prior estimate of $5.40. The consensus estimate for Amgen’s current full-year earnings is $19.52 per share. Zacks Research also issued estimates for Amgen’s Q3 2025 earnings at $5.22 EPS and Q3 2026 earnings at $5.44 EPS.

Several other analysts also recently issued reports on AMGN. William Blair reissued an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $305.00 target price (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price target on shares of Amgen in a research note on Tuesday, November 12th. Oppenheimer reissued an “outperform” rating and issued a $380.00 price objective on shares of Amgen in a research report on Wednesday, August 7th. Finally, Barclays increased their target price on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $333.57.

Amgen Trading Up 1.6 %

AMGN opened at $294.53 on Monday. The stock has a market capitalization of $158.32 billion, a P/E ratio of 37.71, a P/E/G ratio of 2.59 and a beta of 0.60. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen has a 12 month low of $260.68 and a 12 month high of $346.85. The firm’s fifty day simple moving average is $316.52 and its 200 day simple moving average is $318.18.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period last year, the company posted $4.96 EPS.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.06%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is 115.24%.

Hedge Funds Weigh In On Amgen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tudor Financial Inc. bought a new stake in shares of Amgen during the 3rd quarter worth about $3,281,000. Morse Asset Management Inc bought a new stake in shares of Amgen during the third quarter worth approximately $806,000. Virtu Financial LLC acquired a new position in shares of Amgen in the third quarter valued at approximately $1,588,000. TCW Group Inc. increased its stake in shares of Amgen by 6.5% during the third quarter. TCW Group Inc. now owns 276,727 shares of the medical research company’s stock worth $89,164,000 after purchasing an additional 16,984 shares during the period. Finally, Hohimer Wealth Management LLC increased its stake in shares of Amgen by 0.8% during the third quarter. Hohimer Wealth Management LLC now owns 15,358 shares of the medical research company’s stock worth $4,949,000 after purchasing an additional 115 shares during the period. 76.50% of the stock is owned by institutional investors.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.